Table of Content

1 Study Coverage
1.1 Duchenne Muscular Dystrophy Product Introduction
1.2 Market by Type
1.2.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type
1.4.2 Deflazacort
1.4.3 Prednisone
1.2.4 Others
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application
1.3.2 Male
1.3.3 Female
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Duchenne Muscular Dystrophy Sales Estimates and Forecasts 2016-2027
2.2 Global Duchenne Muscular Dystrophy Revenue Estimates and Forecasts 2016-2027
2.3 Global Duchenne Muscular Dystrophy Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Duchenne Muscular Dystrophy Regions by Sales
2.4.1 Global Top Duchenne Muscular Dystrophy Regions by Sales (2016-2021)
2.4.2 Global Top Duchenne Muscular Dystrophy Regions by Sales (2022-2027)
2.5 Global Top Duchenne Muscular Dystrophy Regions by Revenue
2.5.1 Global Top Duchenne Muscular Dystrophy Regions by Revenue (2016-2021)
2.5.2 Global Top Duchenne Muscular Dystrophy Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Duchenne Muscular Dystrophy Sales by Manufacturers
3.1.1 Global Top Duchenne Muscular Dystrophy Manufacturers by Sales (2016-2021)
3.1.2 Global Top Duchenne Muscular Dystrophy Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Sales in 2020
3.2 Global Duchenne Muscular Dystrophy Revenue by Manufacturers
3.2.1 Global Top Duchenne Muscular Dystrophy Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Duchenne Muscular Dystrophy Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Revenue in 2020
3.3 Global Duchenne Muscular Dystrophy Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Duchenne Muscular Dystrophy Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Duchenne Muscular Dystrophy Sales by Type
4.1.1 Global Duchenne Muscular Dystrophy Historical Sales by Type (2016-2021)
4.1.2 Global Duchenne Muscular Dystrophy Forecasted Sales by Type (2022-2027)
4.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2016-2027)
4.2 Global Duchenne Muscular Dystrophy Revenue by Type
4.2.1 Global Duchenne Muscular Dystrophy Historical Revenue by Type (2016-2021)
4.2.2 Global Duchenne Muscular Dystrophy Forecasted Revenue by Type (2022-2027)
4.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2016-2027)
4.3 Global Duchenne Muscular Dystrophy Price by Type
4.3.1 Global Duchenne Muscular Dystrophy Price by Type (2016-2021)
4.3.2 Global Duchenne Muscular Dystrophy Price Forecast by Type (2022-2027)
5 Market Size by Application
5.1 Global Duchenne Muscular Dystrophy Sales by Application
5.1.1 Global Duchenne Muscular Dystrophy Historical Sales by Application (2016-2021)
5.1.2 Global Duchenne Muscular Dystrophy Forecasted Sales by Application (2022-2027)
5.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2016-2027)
5.2 Global Duchenne Muscular Dystrophy Revenue by Application
5.2.1 Global Duchenne Muscular Dystrophy Historical Revenue by Application (2016-2021)
5.2.2 Global Duchenne Muscular Dystrophy Forecasted Revenue by Application (2022-2027)
5.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2016-2027)
5.3 Global Duchenne Muscular Dystrophy Price by Application
5.3.1 Global Duchenne Muscular Dystrophy Price by Application (2016-2021)
5.3.2 Global Duchenne Muscular Dystrophy Price Forecast by Application (2022-2027)

6 North America
6.1 North America Duchenne Muscular Dystrophy Market Size by Type
6.1.1 North America Duchenne Muscular Dystrophy Sales by Type (2016-2027)
6.1.2 North America Duchenne Muscular Dystrophy Revenue by Type (2016-2027)
6.2 North America Duchenne Muscular Dystrophy Market Size by Application
6.2.1 North America Duchenne Muscular Dystrophy Sales by Application (2016-2027)
6.2.2 North America Duchenne Muscular Dystrophy Revenue by Application (2016-2027)
6.3 North America Duchenne Muscular Dystrophy Market Size by Country
6.3.1 North America Duchenne Muscular Dystrophy Sales by Country (2016-2027)
6.3.2 North America Duchenne Muscular Dystrophy Revenue by Country (2016-2027)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Market Size by Type
7.1.1 Europe Duchenne Muscular Dystrophy Sales by Type (2017-2027)
7.1.2 Europe Duchenne Muscular Dystrophy Revenue by Type (2017-2027)
7.2 Europe Duchenne Muscular Dystrophy Market Size by Application
7.2.1 Europe Duchenne Muscular Dystrophy Sales by Application (2017-2027)
7.2.2 Europe Duchenne Muscular Dystrophy Revenue by Application (2017-2027)
7.3 Europe Duchenne Muscular Dystrophy Market Size by Country
7.3.1 Europe Duchenne Muscular Dystrophy Sales by Country (2017-2027)
7.3.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2017-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Duchenne Muscular Dystrophy Market Size by Type
8.1.1 Asia Pacific Duchenne Muscular Dystrophy Sales by Type (2018-2027)
8.1.2 Asia Pacific Duchenne Muscular Dystrophy Revenue by Type (2018-2027)
8.2 Asia Pacific Duchenne Muscular Dystrophy Market Size by Application
8.2.1 Asia Pacific Duchenne Muscular Dystrophy Sales by Application (2018-2027)
8.2.2 Asia Pacific Duchenne Muscular Dystrophy Revenue by Application (2018-2027)
8.3 Asia Pacific Duchenne Muscular Dystrophy Market Size by Region
8.3.1 Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2018-2027)
8.3.2 Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2018-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Market Size by Type
9.1.1 Latin America Duchenne Muscular Dystrophy Sales by Type (2019-2027)
9.1.2 Latin America Duchenne Muscular Dystrophy Revenue by Type (2019-2027)
9.2 Latin America Duchenne Muscular Dystrophy Market Size by Application
9.2.1 Latin America Duchenne Muscular Dystrophy Sales by Application (2019-2027)
9.2.2 Latin America Duchenne Muscular Dystrophy Revenue by Application (2019-2027)
9.3 Latin America Duchenne Muscular Dystrophy Market Size by Country
9.3.1 Latin America Duchenne Muscular Dystrophy Sales by Country (2019-2027)
9.3.2 Latin America Duchenne Muscular Dystrophy Revenue by Country (2019-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
6 Middle East and Africa
6.1 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Type
6.1.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2016-2027)
6.1.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Type (2016-2027)
6.2 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Application
6.2.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2016-2027)
6.2.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Application (2016-2027)
6.3 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Country
6.3.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2016-2027)
6.3.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2016-2027)
6.3.3 Turkey
6.3.4 Saudi Arabia
6.3.5 U.A.E

11 Company Profiles
11.1 PTC Therapeutics
11.1.1 PTC Therapeutics Corporation Information
11.1.2 PTC Therapeutics Overview
11.1.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Description
11.1.5 PTC Therapeutics Related Developments
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Corporation Information
11.2.2 Sarepta Therapeutics Overview
11.2.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Description
11.2.5 Sarepta Therapeutics Related Developments
11.3 Others
11.3.1 Others Corporation Information
11.3.2 Others Overview
11.3.3 Others Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Others Duchenne Muscular Dystrophy Product Description
11.3.5 Others Related Developments
11.1 PTC Therapeutics
11.1.1 PTC Therapeutics Corporation Information
11.1.2 PTC Therapeutics Overview
11.1.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Description
11.1.5 PTC Therapeutics Related Developments

12 Value Chain and Sales Channels Analysis
12.1 Duchenne Muscular Dystrophy Value Chain Analysis
12.2 Duchenne Muscular Dystrophy Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Duchenne Muscular Dystrophy Production Mode & Process
12.4 Duchenne Muscular Dystrophy Sales and Marketing
12.4.1 Duchenne Muscular Dystrophy Sales Channels
12.4.2 Duchenne Muscular Dystrophy Distributors
12.5 Duchenne Muscular Dystrophy Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Duchenne Muscular Dystrophy Industry Trends
13.2 Duchenne Muscular Dystrophy Market Drivers
13.3 Duchenne Muscular Dystrophy Market Challenges
13.4 Duchenne Muscular Dystrophy Market Restraints

14 Key Findings in The Global Duchenne Muscular Dystrophy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Deflazacort
Table 3. Major Manufacturers of Prednisone
Table 4. Major Manufacturers of Others
Table 5. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 6. Global Duchenne Muscular Dystrophy Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 7. Global Duchenne Muscular Dystrophy Sales by Region (2016-2021) & (K Doses)
Table 8. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2016-2021)
Table 9. Global Duchenne Muscular Dystrophy Sales by Region (2016-2021) & (K Doses)
Table 10. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2022-2027)
Table 11. Global Duchenne Muscular Dystrophy Revenue by Region (2016-2021) & (US$ Million)
Table 12. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2016-2021)
Table 13. Global Duchenne Muscular Dystrophy Revenue by Region (2022-2027) & (US$ Million)
Table 14. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2022-2027)
Table 15. Global Duchenne Muscular Dystrophy Sales by Manufacturers (2016-2021) & (K Doses)
Table 16. Global Duchenne Muscular Dystrophy Sales Share by Manufacturers (2016-2021)
Table 17. Global Duchenne Muscular Dystrophy Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 18. Global Duchenne Muscular Dystrophy Revenue Share by Manufacturers (2016-2021)
Table 19. Duchenne Muscular Dystrophy Price by Manufacturers 2016-2021 (USD/Dose)
Table 20. Global Duchenne Muscular Dystrophy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Duchenne Muscular Dystrophy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy as of 2020)
Table 22. Duchenne Muscular Dystrophy Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Duchenne Muscular Dystrophy Product Offered
Table 24. Date of Manufacturers Enter into Duchenne Muscular Dystrophy Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Duchenne Muscular Dystrophy Sales by Type (2016-2021) & (K Doses)
Table 27. Global Duchenne Muscular Dystrophy Sales by Type (2022-2027) & (K Doses)
Table 28. Global Duchenne Muscular Dystrophy Sales Share by Type (2016-2021)
Table 29. Global Duchenne Muscular Dystrophy Sales Share by Type (2022-2027)
Table 30. Global Duchenne Muscular Dystrophy Revenue by Type (2016-2021) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy Revenue by Type (2022-2027) & (US$ Million)
Table 32. Global Duchenne Muscular Dystrophy Revenue Share by Type (2016-2021)
Table 33. Global Duchenne Muscular Dystrophy Revenue Share by Type (2022-2027)
Table 34. Duchenne Muscular Dystrophy Price by Type (2016-2021) & (USD/Dose)
Table 35. Global Duchenne Muscular Dystrophy Price Forecast by Type (2022-2027) & (USD/Dose)
Table 36. Global Duchenne Muscular Dystrophy Sales by Application (2016-2021) & (K Doses)
Table 37. Global Duchenne Muscular Dystrophy Sales by Application (2022-2027) & (K Doses)
Table 38. Global Duchenne Muscular Dystrophy Sales Share by Application (2016-2021)
Table 39. Global Duchenne Muscular Dystrophy Sales Share by Application (2022-2027)
Table 40. Global Duchenne Muscular Dystrophy Revenue by Application (2016-2021) & (US$ Million)
Table 41. Global Duchenne Muscular Dystrophy Revenue by Application (2022-2027) & (US$ Million)
Table 42. Global Duchenne Muscular Dystrophy Revenue Share by Application (2016-2021)
Table 43. Global Duchenne Muscular Dystrophy Revenue Share by Application (2022-2027)
Table 44. Duchenne Muscular Dystrophy Price by Application (2016-2021) & (USD/Dose)
Table 45. Global Duchenne Muscular Dystrophy Price Forecast by Application (2022-2027) & (USD/Dose)
Table 46. North America Duchenne Muscular Dystrophy Sales by Type (2016-2021) & (K Doses)
Table 47. North America Duchenne Muscular Dystrophy Sales by Type (2022-2027) & (K Doses)
Table 48. North America Duchenne Muscular Dystrophy Revenue by Type (2016-2021) & (US$ Million)
Table 49. North America Duchenne Muscular Dystrophy Revenue by Type (2022-2027) & (US$ Million)
Table 50. North America Duchenne Muscular Dystrophy Sales by Application (2016-2021) & (K Doses)
Table 51. North America Duchenne Muscular Dystrophy Sales by Application (2022-2027) & (K Doses)
Table 52. North America Duchenne Muscular Dystrophy Revenue by Application (2016-2021) & (US$ Million)
Table 53. North America Duchenne Muscular Dystrophy Revenue by Application (2022-2027) & (US$ Million)
Table 54. North America Duchenne Muscular Dystrophy Sales by Country (2016-2021) & (K Doses)
Table 55. North America Duchenne Muscular Dystrophy Sales by Country (2022-2027) & (K Doses)
Table 56. North America Duchenne Muscular Dystrophy Revenue by Country (2016-2021) & (US$ Million)
Table 57. North America Duchenne Muscular Dystrophy Revenue by Country (2022-2027) & (US$ Million)
Table 58. Europe Duchenne Muscular Dystrophy Sales by Type (2016-2021) & (K Doses)
Table 59. Europe Duchenne Muscular Dystrophy Sales by Type (2022-2027) & (K Doses)
Table 60. Europe Duchenne Muscular Dystrophy Revenue by Type (2016-2021) & (US$ Million)
Table 61. Europe Duchenne Muscular Dystrophy Revenue by Type (2022-2027) & (US$ Million)
Table 62. Europe Duchenne Muscular Dystrophy Sales by Application (2016-2021) & (K Doses)
Table 63. Europe Duchenne Muscular Dystrophy Sales by Application (2022-2027) & (K Doses)
Table 64. Europe Duchenne Muscular Dystrophy Revenue by Application (2016-2021) & (US$ Million)
Table 65. Europe Duchenne Muscular Dystrophy Revenue by Application (2022-2027) & (US$ Million)
Table 66. Europe Duchenne Muscular Dystrophy Sales by Country (2016-2021) & (K Doses)
Table 67. Europe Duchenne Muscular Dystrophy Sales by Country (2022-2027) & (K Doses)
Table 68. Europe Duchenne Muscular Dystrophy Revenue by Country (2016-2021) & (US$ Million)
Table 69. Europe Duchenne Muscular Dystrophy Revenue by Country (2022-2027) & (US$ Million)
Table 70. Asia Pacific Duchenne Muscular Dystrophy Sales by Type (2016-2021) & (K Doses)
Table 71. Asia Pacific Duchenne Muscular Dystrophy Sales by Type (2022-2027) & (K Doses)
Table 72. Asia Pacific Duchenne Muscular Dystrophy Revenue by Type (2016-2021) & (US$ Million)
Table 73. Asia Pacific Duchenne Muscular Dystrophy Revenue by Type (2022-2027) & (US$ Million)
Table 74. Asia Pacific Duchenne Muscular Dystrophy Sales by Application (2016-2021) & (K Doses)
Table 75. Asia Pacific Duchenne Muscular Dystrophy Sales by Application (2022-2027) & (K Doses)
Table 76. Asia Pacific Duchenne Muscular Dystrophy Revenue by Application (2016-2021) & (US$ Million)
Table 77. Asia Pacific Duchenne Muscular Dystrophy Revenue by Application (2022-2027) & (US$ Million)
Table 78. Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2016-2021) & (K Doses)
Table 79. Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2022-2027) & (K Doses)
Table 80. Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2016-2021) & (US$ Million)
Table 81. Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2022-2027) & (US$ Million)
Table 82. Latin America Duchenne Muscular Dystrophy Sales by Type (2016-2021) & (K Doses)
Table 83. Latin America Duchenne Muscular Dystrophy Sales by Type (2022-2027) & (K Doses)
Table 84. Latin America Duchenne Muscular Dystrophy Revenue by Type (2016-2021) & (US$ Million)
Table 85. Latin America Duchenne Muscular Dystrophy Revenue by Type (2022-2027) & (US$ Million)
Table 86. Latin America Duchenne Muscular Dystrophy Sales by Application (2016-2021) & (K Doses)
Table 87. Latin America Duchenne Muscular Dystrophy Sales by Application (2022-2027) & (K Doses)
Table 88. Latin America Duchenne Muscular Dystrophy Revenue by Application (2016-2021) & (US$ Million)
Table 89. Latin America Duchenne Muscular Dystrophy Revenue by Application (2022-2027) & (US$ Million)
Table 90. Latin America Duchenne Muscular Dystrophy Sales by Country (2016-2021) & (K Doses)
Table 91. Latin America Duchenne Muscular Dystrophy Sales by Country (2022-2027) & (K Doses)
Table 92. Latin America Duchenne Muscular Dystrophy Revenue by Country (2016-2021) & (US$ Million)
Table 93. Latin America Duchenne Muscular Dystrophy Revenue by Country (2022-2027) & (US$ Million)
Table 94. Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2016-2021) & (K Doses)
Table 95. Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2022-2027) & (K Doses)
Table 96. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Type (2016-2021) & (US$ Million)
Table 97. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Type (2022-2027) & (US$ Million)
Table 98. Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2016-2021) & (K Doses)
Table 99. Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2022-2027) & (K Doses)
Table 100. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Application (2016-2021) & (US$ Million)
Table 101. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Application (2022-2027) & (US$ Million)
Table 102. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2016-2021) & (K Doses)
Table 103. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2022-2027) & (K Doses)
Table 104. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2016-2021) & (US$ Million)
Table 105. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2022-2027) & (US$ Million)
Table 106. PTC Therapeutics Corporation Information
Table 107. PTC Therapeutics Description and Major Businesses
Table 108. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 109. PTC Therapeutics Duchenne Muscular Dystrophy Product
Table 110. PTC Therapeutics Recent Developments
Table 111. Sarepta Therapeutics Corporation Information
Table 112. Sarepta Therapeutics Description and Major Businesses
Table 113. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 114. Sarepta Therapeutics Duchenne Muscular Dystrophy Product
Table 115. Sarepta Therapeutics Recent Developments
Table 116. Others Corporation Information
Table 117. Others Description and Major Businesses
Table 118. Others Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 119. Others Duchenne Muscular Dystrophy Product
Table 120. Others Recent Developments
Table 121. Key Raw Materials Lists
Table 122. Raw Materials Key Suppliers Lists
Table 123. Duchenne Muscular Dystrophy Distributors List
Table 124. Duchenne Muscular Dystrophy Customers List
Table 125. Duchenne Muscular Dystrophy Market Trends
Table 126. Duchenne Muscular Dystrophy Market Drivers
Table 127. Duchenne Muscular Dystrophy Market Challenges
Table 128. Duchenne Muscular Dystrophy Market Restraints
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Duchenne Muscular Dystrophy Product Picture
Figure 2. Global Duchenne Muscular Dystrophy Market Share by Type in 2020 & 2027
Figure 3. Deflazacort Product Picture
Figure 4. Prednisone Product Picture
Figure 5. Others Product Picture
Figure 6. Global Duchenne Muscular Dystrophy Sales Market Share by Application in 2020 & 2027
Figure 7. Male
Figure 8. Female
Figure 9. Duchenne Muscular Dystrophy Report Years Considered
Figure 10. Global Duchenne Muscular Dystrophy Sales 2016-2027 (K Doses)
Figure 11. Global Duchenne Muscular Dystrophy Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Duchenne Muscular Dystrophy Revenue 2016-2027 (US$ Million)
Figure 13. Global Duchenne Muscular Dystrophy Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 14. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2016-2021)
Figure 15. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2022-2027)
Figure 16. North America Duchenne Muscular Dystrophy Sales YoY (2016-2027) & (K Doses)
Figure 17. North America Duchenne Muscular Dystrophy Revenue YoY (2016-2027) & (US$ Million)
Figure 18. Europe Duchenne Muscular Dystrophy Sales YoY (2016-2027) & (K Doses)
Figure 19. Europe Duchenne Muscular Dystrophy Revenue YoY (2016-2027) & (US$ Million)
Figure 20. Asia-Pacific Duchenne Muscular Dystrophy Sales YoY (2016-2027) & (K Doses)
Figure 21. Asia-Pacific Duchenne Muscular Dystrophy Revenue YoY (2016-2027) & (US$ Million)
Figure 22. Latin America Duchenne Muscular Dystrophy Sales YoY (2016-2027) & (K Doses)
Figure 23. Latin America Duchenne Muscular Dystrophy Revenue YoY (2016-2027) & (US$ Million)
Figure 24. Middle East & Africa Duchenne Muscular Dystrophy Sales YoY (2016-2027) & (K Doses)
Figure 25. Middle East & Africa Duchenne Muscular Dystrophy Revenue YoY (2016-2027) & (US$ Million)
Figure 26. The Top 10 and Top 5 Players Market Share by Duchenne Muscular Dystrophy Sales in 2020
Figure 27. The Top 10 and Top 5 Players Market Share by Duchenne Muscular Dystrophy Revenue in 2020
Figure 28. Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 29. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2016-2027)
Figure 30. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2016-2027)
Figure 31. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2016-2027)
Figure 32. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2016-2027)
Figure 33. North America Duchenne Muscular Dystrophy Sales Market Share by Type (2016-2027)
Figure 34. North America Duchenne Muscular Dystrophy Revenue Market Share by Type (2016-2027)
Figure 35. North America Duchenne Muscular Dystrophy Sales Market Share by Application (2016-2027)
Figure 36. North America Duchenne Muscular Dystrophy Revenue Market Share by Application (2016-2027)
Figure 37. North America Duchenne Muscular Dystrophy Sales Share by Country (2016-2027)
Figure 38. North America Duchenne Muscular Dystrophy Revenue Share by Country (2016-2027)
Figure 39. U.S. Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 40. Canada Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 41. Europe Duchenne Muscular Dystrophy Sales Market Share by Type (2016-2027)
Figure 42. Europe Duchenne Muscular Dystrophy Revenue Market Share by Type (2016-2027)
Figure 43. Europe Duchenne Muscular Dystrophy Sales Market Share by Application (2016-2027)
Figure 44. Europe Duchenne Muscular Dystrophy Revenue Market Share by Application (2016-2027)
Figure 45. Europe Duchenne Muscular Dystrophy Sales Share by Country (2016-2027)
Figure 46. Europe Duchenne Muscular Dystrophy Revenue Share by Country (2016-2027)
Figure 47. Germany Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 48. France Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 49. U.K. Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 50. Italy Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 51. Russia Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 52. Asia Pacific Duchenne Muscular Dystrophy Sales Market Share by Type (2016-2027)
Figure 53. Asia Pacific Duchenne Muscular Dystrophy Revenue Market Share by Type (2016-2027)
Figure 54. Asia Pacific Duchenne Muscular Dystrophy Sales Market Share by Application (2016-2027)
Figure 55. Asia Pacific Duchenne Muscular Dystrophy Revenue Market Share by Application (2016-2027)
Figure 56. Asia Pacific Duchenne Muscular Dystrophy Sales Share by Region (2016-2027)
Figure 57. Asia Pacific Duchenne Muscular Dystrophy Revenue Share by Region (2016-2027)
Figure 58. China Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 59. Japan Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 60. South Korea Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 61. India Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 62. Australia Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 63. Taiwan Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 64. Indonesia Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 65. Thailand Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 66. Malaysia Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 67. Philippines Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 68. Latin America Duchenne Muscular Dystrophy Sales Market Share by Type (2016-2027)
Figure 69. Latin America Duchenne Muscular Dystrophy Revenue Market Share by Type (2016-2027)
Figure 70. Latin America Duchenne Muscular Dystrophy Sales Market Share by Application (2016-2027)
Figure 71. Latin America Duchenne Muscular Dystrophy Revenue Market Share by Application (2016-2027)
Figure 72. Latin America Duchenne Muscular Dystrophy Sales Share by Country (2016-2027)
Figure 73. Latin America Duchenne Muscular Dystrophy Revenue Share by Country (2016-2027)
Figure 74. Mexico Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 75. Brazil Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 76. Argentina Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 77. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Type (2016-2027)
Figure 78. Middle East and Africa Duchenne Muscular Dystrophy Revenue Market Share by Type (2016-2027)
Figure 79. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Application (2016-2027)
Figure 80. Middle East and Africa Duchenne Muscular Dystrophy Revenue Market Share by Application (2016-2027)
Figure 81. Middle East and Africa Duchenne Muscular Dystrophy Sales Share by Country (2016-2027)
Figure 82. Middle East and Africa Duchenne Muscular Dystrophy Revenue Share by Country (2016-2027)
Figure 83. Turkey Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 84. Saudi Arabia Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 85. U.A.E Duchenne Muscular Dystrophy Revenue (2016-2027) & (US$ Million)
Figure 86. Duchenne Muscular Dystrophy Value Chain
Figure 87. Duchenne Muscular Dystrophy Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed